Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Improved Imaging for Neovascular Development in Congenital Heart Disease Research
Published on: April 26, 2024
Guideline compliance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and
M J Moesker1, J F de Groot2, N L Damen3
11Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081BT Amsterdam, The Netherlands.
Insights
Bridging anticoagulation for vitamin-K antagonist patients undergoing procedures showed significant guideline non-compliance. Individual risk factors, not aggregated guideline risk, influenced clinical decisions, highlighting a need for improved practice.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Practice Guidelines
Background:
- Bridging anticoagulation is a complex process for patients on vitamin-K antagonists (VKAs) requiring invasive procedures.
- It involves intricate risk assessment to prevent both thromboembolic events and bleeding complications.
Purpose of the Study:
- To evaluate adherence to established guidelines for bridging anticoagulation in VKA patients.
- To identify factors influencing the decision to use bridging anticoagulation, particularly non-compliant practices.
Main Methods:
- A retrospective analysis of 256 patient records across 13 Dutch hospitals.
- Data collected included demographics, clinical details, surgical factors, and care delivery characteristics.
- Compliance with the American College of Chest Physicians ninth edition guideline (AT9) was assessed using multilevel regression models.
Main Results:
- Bridging anticoagulation use varied widely between hospitals (15.0%–83.3%), with guideline compliance also differing significantly (20.0%–88.2%).
- Factors beyond aggregated thromboembolic risk, such as gastrointestinal or vascular surgery and non-elective procedures, predicted bridging use.
- Lower socioeconomic status and VKA reversal agent use were associated with reduced bridging.
Conclusions:
- Approximately 31.5% of patients did not receive bridging anticoagulation compliant with AT9 guidelines.
- Individual thromboembolic risk factors and other clinical characteristics were more influential in decision-making than the AT9 aggregated risk.
- Significant heterogeneity in guideline implementation across hospitals necessitates further research and interventions to optimize bridging anticoagulation practices.
Background:
Bridging anticoagulation is used in vitamin-K antagonist (VKA) patients undergoing invasive procedures and involves complex risk assessment in order to prevent thromboembolic and bleeding outcomes.
Objectives:
Our aim was to assess guideline compliance and identify factors associated with bridging and especially, non-compliant bridging.
Methods:
A retrospective review of 256 patient records in 13 Dutch hospitals was performed. Demographic, clinical, surgical and care delivery characteristics were collected. Compliance to the American College of Chest Physicians ninth edition guideline (AT9) was assessed. Multilevel regression models were built to explain bridging use and predict non-compliance.
Results:
Bridging use varied from 15.0 to 83.3% (mean = 41.8%) of patients per hospital, whereas guideline compliance varied from 20.0 to 88.2% (mean = 68.5%) per hospital. Both established thromboembolic risk factors and characteristics outside thromboembolic risk assessment were associated with bridging use. Predictors for overuse were gastrointestinal surgery (OR 14.85, 95% CI 2.69-81.99), vascular surgery (OR 13.01, 95% CI 1.83-92.30), non-elective surgery (OR 8.67, 95% CI 1.67-45.14), lowest 25th percentile socioeconomic status (OR 0.33, 95% CI 0.11-1.02) and use of VKA reversal agents (OR 0.22, 95% CI 0.04-1.16).
Conclusion:
Bridging anticoagulation practice was not compliant with the AT9 in 31.5% of patients. The aggregated AT9 thromboembolic risk was inferior to individual thromboembolic risk factors and other characteristics in explaining bridging use. Therefor the AT9 risk seems less important for the decision making in everyday practice. Additionally, a heterogeneous implementation of the guideline between hospitals was found. Further research and interventions are needed to improve bridging anticoagulation practice in VKA patients.
More Related Videos
10:19Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
Published on: August 22, 2014
11:05SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients
Published on: February 6, 2021
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
What is Variation?
The range, standard deviation, standard error, and variance are the different measures of variation.
Range: The range is the difference between its maximum and...
Vitamins
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Bridge rectifier
Operationally, the bridge rectifier allows current flow through two of its diodes during each...